Sign in3 stories
The Dallas biotech is selling 1,469,725 shares at $1.09 each alongside pre-funded warrants priced at $1.0899, with net proceeds earmarked for working capital.
SEC filing
The Dallas oncology company priced shares at $1.09 and pre-funded warrants at $1.0899, with a concurrent private placement of matching purchase warrants.
SEC filing
Lantern's Q2 2026 update covers a new AI subsidiary, an EGFR L858R lung cancer data update, an EMA-cleared bladder cancer trial, and $7.4 million in cash.
SEC filing